Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

Ewing's Sarcoma Clinical Trial

Official title:

Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01222767
• Other study ID #: PM104-B-003-10
• Status: Completed
• Phase: Phase 2
• Start date: December 2010
• Est. completion date: April 2012

Study information

• Verified date: July 2021
• Source: PharmaMar
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy to determine the antitumor activity of Zalypsis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

1. Voluntary written informed consent, obtained from the patient or his/her representative before the beginning of any specific study procedures.

2. Age = 16 years.

3. Histologically or cytologically confirmed EFT (Ewing Family of Tumors), with recurrent disease.

4. Documented failure to at least one prior chemotherapy regimen for their disease.

5. Radiographic documentation of disease progression at study entry.

6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score = 2.

7. Life expectancy = 3 months.

8. Complete recovery from the effects of drug-related adverse events (AEs) derived from previous treatments, excluding alopecia and grade 1 peripheral neuropathy, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v. 4.0.

9. At least one measurable lesion ("target lesion" according to the RECIST v.1.1), located in a non-irradiated area and adequately measured less than four weeks before study entry. Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is clearly documented or biopsy proven.

10. Absolute neutrophil count (ANC) = 1.5 x 109/l; platelet count = 100 x 109/l, and hemoglobin = 9 g/dl.

11. Adequate renal function: calculated creatinine clearance (using Cockcroft and Gault's formula) = 30 ml/min.

12. Adequate hepatic function:

• Total bilirubin = 1.5 x upper limit or normality (ULN), unless due to Gilbert's syndrome.

• Alanine aminotransferase (ALT), aspartate aminotransferase (AST) = 3 x ULN (= 5 x ULN in case of hepatic metastases), and alkaline phosphatase (AP) = 2.5 x ULN (= 5 x ULN in case of extensive bone involvement).

• Albumin = 25 g/l.

13. Left ventricular ejection fraction (LVEF) within normal limits (LVEF of at least 50%).

14. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for three months after discontinuation of treatment. Acceptable methods of contraception include complete abstinence, intrauterine device (IUD), oral contraceptive, subdermal implant and double barrier (condom with a contraceptive sponge or contraceptive suppository).

Exclusion Criteria:

1. Prior therapy with Zalypsis®.

2. Pregnant or lactating women or women of childbearing potential not using an appropriate contraceptive method.

3. Less than three weeks from prior radiation therapy, biological therapy or chemotherapy.

4. Less than six weeks from prior nitrosourea, mitomycin C, high-dose chemotherapy or radiotherapy involving the whole pelvis or over 50% of the spine, provided that acute effects of radiation treatment have resolved. Hormonal therapy and palliative radiation therapy (i.e., for control of pain from bone metastases) must be discontinued before study entry.

5. Patients with a prior invasive malignancy (except non-melanoma skin cancer and in situ cervix carcinoma) who have had any evidence of disease within the last five years or whose prior malignancy treatment contraindicates the current protocol therapy.

6. Evidence of progressive or symptomatic central nervous system (CNS) metastases or leptomeningeal metastases.

7. Other diseases or serious conditions:

• Increased cardiac risk, as defined by:

• Unstable angina or myocardial infarction within 12 months before inclusion in the study.

• New York Heart Association (NYHA) grade II or greater congestive heart failure.

• Symptomatic arrhythmia or any arrhythmia requiring ongoing treatment.

• Abnormal electrocardiogram (ECG), i.e., patients with the following are excluded: QT prolongation - QTc > 480 msec; signs of cardiac enlargement or hypertrophy; bundle branch block; partial blocks; signs of ischemia or necrosis, and Wolff Parkinson White patterns.

• History or presence of valvular heart disease.

• Uncontrolled arterial hypertension despite optimal medical therapy.

• Previous mediastinal radiotherapy.

• Previous treatment with doxorubicin at cumulative doses exceeding 400 mg/m2.

• History of significant neurological or psychiatric disorders.

• Active infection requiring systemic treatment.

• Significant non-neoplastic liver disease (e.g., cirrhosis).

• Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

• Immunocompromised patients, including those known to be infected with the human immunodeficiency virus (HIV).

• Uncontrolled (i.e., requiring relevant changes in medication within the last month or hospital admission within the last three months) endocrine diseases (e.g., diabetes mellitus, hypo- or hyperthyroidism, adrenal disorder).

8. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in the study. The Investigator should feel free to consult the Study Coordinator or the Sponsor(s) in case of uncertainty in this regard.

9. Limitation of the patient's ability to comply with the treatment or to follow-up at a participating center. Patients enrolled into this trial must be treated and followed at a participating center.

10. Treatment with any investigational product within 30 days prior to inclusion in the study.

11. Known hypersensitivity to any component of Zalypsis®.

Related Conditions & MeSH terms

• Askin's Tumor of the Chest Wall
• Ewing's Sarcoma
• Extraosseous Ewing's Sarcoma (EOE)
• Neoplasms
• Neuroectodermal Tumors
• Neuroectodermal Tumors, Primitive
• Neuroectodermal Tumors, Primitive, Peripheral
• Primitive Neuroectodermal Tumor (PNET)
• Sarcoma
• Sarcoma, Ewing

Intervention

Drug:
• Zalypsis
Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.

Locations

Country	Name	City	State
France	Centre Léon Bérard	Lyon
Italy	Istituto Ortopedici Rizzoli	Bologna
Italy	Istituto Nazionale dei Tumori	Milan
Italy	Istituto Clinico Humanitas	Rozzano
United States	St. Jude Children 's Research Hospital	Memphis	Tennessee
United States	Sarcoma Oncology Center	Santa Monica	California
United States	Seattle Cancer Care Alliance	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
PharmaMar

Countries where clinical trial is conducted

United States,  France,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	Overall response rate (ORR), defined as the percentage of patients with confirmed objective response (OR), either CR or PR according to the RECIST v.1.1.; CR, complete response: disappearance of all lesions; PD, disease progression: =10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: =10% decrease in target lesion size or =15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; RECIST, Response Evaluation Criteria in Solid Tumors	At baseline and every other cycle (± 1 week) until evidence of PD, up to 2 years
Secondary	Best Tumor Response	Best tumor response was defined as the best response achieved during the study according to RECIST v1.1 CR, complete response: disappearance of all lesions; PD, disease progression: =10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: =10% decrease in target lesion size or =15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; RECIST, Response Evaluation Criteria in Solid Tumors	At baseline and every other cycle (± 1 week) until evidence of PD, up to 2 years
Secondary	Progression-free Survival	Progression-free survival (PFS), defined as the time from the first day of study treatment to the day of negative assessment (progression or death), start of subsequent antitumor therapy, or last tumor evaluation.; PD, disease progression: =10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: =10% decrease in target lesion size or =15% decrease in tumor density	From the first day of study treatment to the day of negative assessment (progression or death), start of subsequent antitumor therapy, or last tumor evaluation, up to 2 years
Secondary	Progression-free Survival at 3 Months	Progression-free survival (PFS), defined as the time from the first day of study treatment to the day of negative assessment (progression or death), start of subsequent antitumor therapy, or last tumor evaluation.; PD, disease progression: =10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: =10% decrease in target lesion size or =15% decrease in tumor density	At 3 months
Secondary	Overall Survival	Overall survival (OS), defined as the time from the first day of treatment to the date of death (or the last day when the patient was known to be alive). Survival was to be followed for up to six months after the last treatment visit of the last patient, or 12 months after the last patient was included, whichever occurred first.	from the first day of treatment to the date of death, up to 2 years
Secondary	Overall Survival Rate at 6 Months	Overall survival (OS), defined as the time from the first day of treatment to the date of death (or the last day when the patient was known to be alive). Survival was to be followed for up to six months after the last treatment visit of the last patient, or 12 months after the last patient was included, whichever occurred first.	At 6 months
Secondary	Overall Survival Rate at 12 Months	Overall survival (OS), defined as the time from the first day of treatment to the date of death (or the last day when the patient was known to be alive). Survival was to be followed for up to six months after the last treatment visit of the last patient, or 12 months after the last patient was included, whichever occurred first.	At 12 months
Secondary	PM00104 Plasma PK Parameters (Cmax) at First Infusion	Cmax Maximum plasma concentration, directly determined from the experimental data	0 (Pre-infusion) and 5 min, 30 min, 2 hours, 6 hours, 24 hours, 48 hours and 168 hours after the end of first infusion (Day 1)
Secondary	PM00104 Plasma PK Parameters (AUC) at First Infusion	AUC Area under the plasma concentration-time curve from time zero to infinity	0 (Pre-infusion) and 5 min, 30 min, 2 hours, 6 hours, 24 hours, 48 hours and 168 hours after the end of first infusion (Day 1)
Secondary	PM00104 Plasma PK Parameters (Cmax) at Second Infusion	Cmax Maximum plasma concentration, directly determined from the experimental data	0 (Pre-infusion) and 5 min, 30 min, 2 hours, 6 hours, 24 hours, 48 hours and 168 hours after the end of second infusion (Day 8)
Secondary	PM00104 Plasma PK Parameters (AUC) at Second Infusion	AUC Area under the plasma concentration-time curve from time zero to infinity	0 (Pre-infusion) and 5 min, 30 min, 2 hours, 6 hours, 24 hours, 48 hours and 168 hours after the end of second infusion (Day 8)